Related Experiment Video
Updated: Aug 15, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
[Dilated cardiomyopathy as a side effect of treatment with infliximab]
Tina H Leetmaa1, John D Markenvard
1Fredericia Sygehus, Medicinsk Afdeling. busybee@get2net.dk
Abstract:
We report a case of heart failure after infusion of Remicade (infliximab) in a patient without heart insufficiency. The patient, a 25-year-old woman with inflammatory bowel disease, developed new-onset heart failure after receiving TNF antagonist therapy. After the treatment was discontinued and heart failure therapy was started, the patient improved significantly. The U.S. Food and Drug Administration has published 47 case reports of heart failure after therapy with a tumor necrosis factor antagonist, where 38 patients developed new-onset heart failure and 9 patients experienced heart failure exacerbation. There are no published reports of heart failure after TNF antagonist therapy in the Danish literature.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
Cardiomyopathy V: Interprofessional Care